N@N

Positive H1N1 (Swine Flu) Virus Initial Pilot Animal Study May Support Use of SinoFresh Nasal Spray as Preventative Measure

_{//health-fitness.news-articles.net/content/2009/ .. nofresh-nasal-spray-as-preventative-measure.html}
^{Published in Health and Fitness on Monday, December 14th 2009 at 6:27 GMT by Market Wire}  

VENICE, FL--(Marketwire - December 14, 2009) - SinoFresh Healthcare, Inc., (PINKSHEETS: [ SFSH ]) announced the recent successful initial animal pilot study of the SinoFresh Nasal Spray product for use in preventing and decreasing the severity of H1N1 ("swine flu") virus. Additional testing necessary for FDA approval of the product for this use, as well as a product specifically targeted at cold and flu including H1N1, is planned. The study suggests that SinoFresh Nasal Spray use allowed the H1N1 infected animals to recover more rapidly than did untreated animals.

The study conducted by SRS International Corp. of Falls Church, VA was designed to evaluate the severity of infection from H1N1 ("swine flu") virus in a well accepted rodent model for studying human nasal and respiratory tract infection by viruses and other microbial pathogens. In the study, the test animals were inoculated with H1N1 and then received SinoFresh Nasal Spray in the nose three times daily for 14 days.

Dr. John A. Todhunter, President of SRS International, who conducted the testing said, "We believe that SinoFresh Homeopathic Antiseptic Nasal Spray's current and past test results supporting a broad killing capability against numerous viruses, bacteria and other pathogens should make the product an excellent candidate for eventual evaluation by the FDA as a safe, broad based preventative antiseptic nasal and sinus cleansing product, which could be used by consumers to enhance current disease prevention measures such as using hand sanitizers and antiseptic mouthwash."

Drs. Michael Stampar, D.O. and Cathy Criss, D.O., Senior Medical Advisors to the Company stated, "In our opinion, these test results are consistent with our nearly eight years of clinical experience and observations using SinoFresh. When coupled with prior SinoFresh testing results, it further confirms our belief that SinoFresh Homeopathic Antiseptic Nasal Spray is on track to be recognized as a breakthrough solution in helping to prevent and/or reduce the severity of a broad range of upper respiratory infections caused by airborne pathogens."

About SinoFresh™ HealthCare, Inc.

SinoFresh™ HealthCare, Inc. is a developer and marketer of therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms suspected of causing pathogenesis of the mouth nose and throat. The Company holds certain patents and patent applications on its innovative pharmaceutical technology and relies upon a panel of medical experts and management team experienced in the bio-pharmaceutical industry.

The Company's product, SinoFresh™ Nasal & Sinus Care, is the only over-the-counter antiseptic nasal spray that kills bacteria and fungi and viral pathogens in the throat and nasal passages. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that affects many Americans annually. More information is available at [ www.sinofresh.com ].

*SinoFresh™ is a trademark of SinoFresh HealthCare, Inc.

Follow us on Twitter. Become a fan on Facebook.

For further information company can be contacted at 888-460-4774, or on the web at [ www.sinofreshproducts.com ], or by email at [ customerservice@sinofreshproducts.com ].

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange commission, including risks summarized in the company's annual Report of form 10-KSB for its fiscal year ended December 31, 2006 (file No.49764). The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments.